Key Insights

Highlights

Success Rate

75% trial completion

Published Results

18 trials with published results (32%)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 59/100

Termination Rate

17.9%

10 terminated out of 56 trials

Success Rate

75.0%

-11.5% vs benchmark

Late-Stage Pipeline

7%

4 trials in Phase 3/4

Results Transparency

60%

18 of 30 completed with results

Key Signals

18 with results75% success

Data Visualizations

Phase Distribution

49Total
Not Applicable (3)
P 1 (18)
P 2 (24)
P 3 (3)
P 4 (1)

Trial Status

Completed30
Terminated10
Recruiting7
Unknown6
Withdrawn2
Active Not Recruiting1

Trial Success Rate

75.0%

Benchmark: 86.5%

Based on 30 completed trials

Clinical Trials (56)

Showing 20 of 20 trials
NCT06698822Phase 2RecruitingPrimary

A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma (CTCL), Stages IA, IB, and IIA

NCT07055477Phase 1Recruiting

A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)

NCT05296304Phase 1RecruitingPrimary

A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides

NCT04447027Phase 1CompletedPrimary

Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies

NCT00177268RecruitingPrimary

Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research

NCT04234048Phase 1Recruiting

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

NCT02512497Phase 1CompletedPrimary

Romidepsin Maintenance After Allogeneic Stem Cell Transplantation

NCT06285370Phase 4Active Not RecruitingPrimary

A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy

NCT05106192Not ApplicableWithdrawn

Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System.

NCT06382844RecruitingPrimary

Novel Flow-cytometry Approaches to Improve the Detection of Tumor Cells in CTCL

NCT05333367Not ApplicableRecruitingPrimary

MORPHEE : Mechanisms of Cell Death Induced by Extracorporeal Photochemotherapy

NCT03493451Phase 2Completed

Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms

NCT00341939Completed

Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data

NCT01728805Phase 3CompletedPrimary

Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL

NCT01226472Phase 2Completed

Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001

NCT06037239Phase 1UnknownPrimary

Phase I/II Study of Linperlisib Plus Chidamide for R/R Cutaneous T-cell Lymphoma: a Prospective, Single-center Study

NCT00071071Phase 2CompletedPrimary

Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in the Skin.

NCT00896493Phase 2Completed

Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma

NCT00071084Phase 2CompletedPrimary

Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin.

NCT03775525Phase 1Unknown

Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer

Scroll to load more

Research Network

Activity Timeline